Cationic liposomeeDNA (CLeDNA) complexes are being pursued as nonviral gene delivery systems for use in applications that include clinic trials. However, to compete with viral vectors for systemic delivery in vivo, their efficiencies and pharmacokinetics need to be improved. The addition of poly (ethylene glycol)-lipids (PEGylation) prolongs circulation lifetimes of liposomes, but inhibits cellular uptake and endosomal escape of CLeDNA complexes. We show that this limits their transfection efficiency (TE) in a manner dependent on the amount of PEG-lipid, the lipid/DNA charge ratio, and the lipid membrane charge density. To improve endosomal escape of PEGylated CLeDNA complexes, we prepared an acidlabile PEG-lipid (HPEG2K-lipid, PEG MW 2000) which is designed to lose its PEG chains at the pH of late endosomes. The HPEG2K-lipid and a similar but acid-stable PEG-lipid were used to prepare PEGylated CLeDNA complexes. TLC and dynamic light scattering showed that HPEG2K-CLeDNA complexes are stable at pH 7.4 for more than 24 h, but the PEG chains are cleaved at pH 5 within 1 h, leading to complex aggregation. The acid-labile HPEG2K-CLeDNA complexes showed enhanced TE over complexes stabilized with the acid-stable PEG-lipid. Live-cell imaging showed that both types of complexes were internalized to quantitatively similar particle distributions within the first 2 h of incubation with cells. Thus, we attribute the increased TE of the HPEG2K-CLeDNA complexes to efficient endosomal escape, enabled by the acid-labile HPEG2K-lipid which sheds its PEG chains in the low pH environment of late endosomes, effectively switching on the electrostatic interactions that promote fusion of the membranes of complex and endosome.
Introduction
Gene therapy is a promising approach in medicine, which is applicable to a wide variety of diseases. Numerous clinical trials are ongoing, with the majority focusing on cancer [1e4]. However, improved vectors for nucleic acid delivery are needed for gene therapy to reach its potential. Nonviral (synthetic) vectors, such as complexes of DNA with cationic lipids or polymers, are desirable because they possess low immunogenicity, can easily be scaled up and chemically modified, and can transfer DNA of any size [5e10]. However, in comparison with viral vectors, their transfection efficiency (TE) is lower, and their pharmacokinetic properties in vivo suffer from their poor colloidal stability [11e16] . Thus, development of nonviral vectors for systemic in vivo applications remains a major challenge [17] .
Specific challenges for in vivo applications of CLeDNA complexes and other nonviral vectors include their rapid clearance from circulation and activation of the complement system [18, 19] . A strategy to address these challenges is surface functionalization of CLeDNA complexes by poly (ethylene glycol) (PEG)-lipids, resulting in steric stabilization. This reduces the nonspecific interactions of CLeDNA complexes and blood components and is well known to increase circulation time for liposomes [20e22] . However, the steric shielding due to PEGylation not only reduces undesired interactions, but also suppresses the electrostatic interactions required for cellular uptake [23] . In addition, it interferes with endosomal escape of complexes by inhibiting fusion of the membranes of the complex with those of the endosome [24, 25] . Both of these processes are keys steps in the transfection mechanism. Endosomal escape, in particular, is a critical step in achieving successful transfection [26, 27] , and the TElimiting step for lamellar complexes of low to intermediate membrane charge density [28, 29] . After uptake by endocytosis, the DNA cargo of complexes which are unable to escape from endosomes eventually gets degraded as endosomes mature and fuse with lysosomes.
There are multiple design strategies that can be implemented to overcome the barriers associated with the use of PEGylation, such as tethering a specific ligand to improve low binding and uptake into the targeted cells [30e32], or designing the PEG shield to be pH-sensitive to enhance endosomal escape [33] . The latter approach has been explored widely with liposomes [34e38], and has also found some recent application with complexes of cationic polymers and nucleic acids (polyplexes) [39e43] . The only (to the best of our knowledge) work reporting use of this approach in CLeDNA complexes [44] applied an orthoester-based PEG-lipid.
We have designed and synthesized an acylhydrazone-based acid-labile PEG-lipid (HPEG2K-lipid, PEG MW 2000) that is stable at physiological pH, but whose PEG chain will be cleaved from the tail at lower pH, such as occurs intracellularly in maturing endosomes [45] . Thus, complexes containing HPEG2K-lipid will be sterically stabilized in the extracellular environment but lose their PEG shell in the endosome, which in turn should allow for more efficient endosomal escape of the complex because the electrostatic interactions between the membranes of complex and endosome are no longer inhibited (cf. Fig. 1 ). We prepared CLeDNA complexes containing HPEG2K-lipid and, for comparison, a similar but low pH-stable PEG-lipid (PEG2K-lipid), starting from mixtures of the neutral lipid 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) with univalent cationic 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or a custom-synthesized pentavalent cationic lipid (MVL5 [46] ). The cationic lipid content was fixed at 80% mol DOTAP and 50% mol MVL5, respectively, which is in the membrane charge density (s M , average charge/unit area of membrane) regime optimal for transfection [29] . We compared PEGylated complexes containing PEG2K-lipid vs. HPEG2K-lipid using dynamic light scattering (DLS, to identify their time-dependent and pH-dependent colloidal stability), live-cell imaging (to assess intracellular particle distributions), and TE measurements.
Materials and methods

Synthesis
An acylhydrazone-based PEG2000-lipid and a structurally similar but low pH-stable PEG2000-lipid were synthesized according to the procedure described in the Supplementary Material. The synthesis and chemical structure of these PEG-lipids are shown in Scheme 1.
Liposome preparation
Lipofectamine 2000 was purchased from Invitrogen and used as per manufacturer's instructions. DOTAP and DOPC were purchased as solutions in chloroform from Avanti Polar Lipids (Alabaster, AL). MVL5 was synthesized as described previously [46] . For calculation of the lipid to DNA charge ratio r, full protonation (headgroup charge þ5e) was assumed for MVL5. All lipids were dissolved in chloroform/methanol (9:1, v/v), and these solutions were mixed at the appropriate ratios in glass vials, dried under a stream of nitrogen, and then placed in a vacuum (rotary vane pump) for 8e12 h. To the resulting thin lipid film, sterile high resistivity (18.2 MU cm) water was added, and the mixture was incubated at 37 C for at least 12 h. The final total lipid concentration was 1 mM. All aqueous lipid solutions were sonicated prior to use and stored at 4 C.
Dynamic light scattering
The diameter of CLeDNA complexes was measured using a Dynapro Nanostar dynamic light scattering (DLS) instrument (Wyatt) and Dynamics 7 software. 
Cell culture and transfection [47]
Luciferase plasmid DNA (pGL3 Control Vector, Promega) was propagated in E. coli and isolated using a Qiagen Giga Kit. Mouse fibroblast L-cells (ATCC number: CCL-1) were maintained at 37 C in supplemented culture medium (Dulbecco's Modified Eagle's Medium (DMEM), containing 5% fetal bovine serum (Thermo Scientific) and 1% penicillin (Invitrogen) in a humidified atmosphere with 5% CO 2 and reseeded approximately every 72 h to maintain subconfluency. For transfection, 80,000 cells/well were seeded in 24-well plates and incubated for 18e24 h prior to transfection. A solution of pGL3 plasmid DNA (4 mg/mL in Opti-MEM) was prepared from a DNA stock solution at 1.4 mg/mL. Appropriate volumes of liposome solutions (to yield the desired lipid to DNA charge ratio) were diluted with Opti-MEM. Equal volumes of liposome and DNA solutions were combined, and 200 mL of this mixture (containing 0.4 mg DNA) were added per well after incubation for 20 min at room temperature. After 6 h incubation at 37 C, the transfection medium was removed, each well was washed once with PBS, and fresh culture medium was added to each well. After another 20e24 h of incubation, cells were harvested in 150 mL of Passive Lysis Buffer (Promega), and luciferase expression was measured as per the assay manufacturer's (Promega) instructions. A multilabel counter (PerkineElmer 1420 Victor3 V) was used to measure the relative light units (RLU) from the luminescence assay. Data points shown are the average of duplicate (and in some cases quadruplicate) measurements, with error bars showing the standard deviation. All experiments were repeated 2e3 times to ascertain reproducibility.
Cytotoxicity
Cytoxicity was assessed using the CellTiter 96 Aqueous One assay (Promega) for cell viability. Mouse fibroblast L-cells were seeded in 96-well plates (15,000 cells/ well) in DMEM medium supplemented with 5% FBS and 1% penicillin. After 18e24 h incubation, the cells were washed once with PBS, and subsequently 40 mL solution including medium and complexes were added (transfection concentration; 0.08 mg DNA per well). After 6 h incubation, the complex-containing medium was replaced by a mixture of 60 mL of Opti-MEM and 20 mL of the Cell Proliferation Assay.
Following 2 h of incubation, absorbance at 490 nm was measured using a scanning multi-well spectrophotometer. The experiment was performed simultaneously for all lipids and the results were normalized to control wells, which differed from the experimental wells only in that they were treated with Opti-MEM instead of PEGylated complexes. Each data point represents the average of at least quadruplicate measurements, with error bars showing the standard deviation.
Optical microscopy
Mouse fibroblast L-cells were grown to 70% confluency on poly(L-lysine)-coated glass coverslips (22 mm). The coverslips were mounted in a closed, temperaturecontrolled chamber from Harvard Apparatus (Model #P2 and RC21-B). Images were acquired using a Nikon Diaphot 300 equipped with a Sensicam QE CCD. Brightfield images were acquired at 60-fold magnification in differential interference contrast (DIC) mode. CLeDNA complexes were prepared at transfection concentration by combining appropriate volumes of solutions of fluorescently labeled liposomes (2 mM; 0.2% (of lipid weight) TRITC-DHPE (Molecular Probes)) and plasmid DNA (0.1 mg/ml stock, labeled with Cy5; diluted with Opti-MEM to the desired concentration). DNA was labeled using the Mirus Label IT Nucleic Acid Labeling Kit according to the manufacturer's protocol. The complexes were incubated for 20 min at room temperature and then added to the cells (maintained at 37 C).
An automated Matlab routine was used to measure the uptake of particles at various time points (see also Fig. 6C ). The routine located intracellular fluorescent particles containing Cy5 and measured the closest distance to the nuclear membrane (the DIC image was used to locate the nucleus). The cell boundary was determined using the brightfield image or the fluorescent image: early time points show a high number of fluorescent particles coating the plasma membrane which allows for clear visualization of the cell boundary in fluorescent micrographs.
Results and discussion
To enable applications of nonviral vectors in systemic gene therapy in vivo, vectors with prolonged circulation times and high transfection efficiency (TE) need to be developed. Prolonged circulation may be achieved by PEGylation as shown for liposomes, but this significantly decreases TE. Causes for the drop in TE are inhibition of the electrostatic interactions between complexes and the cell surface, and interference of the PEG coat with the membrane fusion processes required for endosomal escape. One approach to counteract the latter effect is to attach the PEG chains with a pH-sensitive linker which is stable at neutral pH (the pH of blood) but will be cleaved at pH 5 to 4, the pH of late endosomes. Fig. 1 schematically depicts the rationale for this approach: after complexes are taken up by the cell via endocytosis (left and middle), the endosome matures, and its contents are acidified. This cleaves the PEG chains from the HPEG2K-lipid, allowing closer contact between the membranes of complex and endosomes and thus facilitating escape of the CLeDNA complex via membrane fusion, which is mediated by electrostatic interactions. In other words, synthetic modification of the PEG-lipid enables a physicochemical route for endosomal escape as the contents of the endosome are acidified.
Lipid design and synthesis
To investigate this approach in detail, we designed and synthesized a new acid-labile PEG-lipid (HPEG2K-lipid) featuring an acylhydrazone bond which is prone to hydrolysis at low pH [39] . The HPEG2K-lipid was synthesized following the steps shown in Scheme 1. The lipid tail building block 3,4-dioleyloxybenzoic acid (DOB) [48, 49] was coupled with b-alanine ethyl ester and the resulting ester treated with hydrazine to give acylhydrazide 1. To prepare the HPEG2K-lipid, this was reacted under anhydrous conditions with the aldehyde of PEG2000 monomethylether (mPEG2000), prepared via TEMPO oxidation [50] . In the structure of the HPEG2K-lipid in Scheme 1, the lipid tails are underlain in tan, the acid-labile acylhydrazone moiety in red, and the PEG chain in blue. TLC analysis shows that the HPEG2K-lipid is stable at pH 7.4, but quickly degrades at pH 4 to 5 (see Supplementary Material). The synthesis and structure of the acid-stable (on the time-scale of intracellular processing) PEG2K-lipid, which was prepared by esterification of DOB with mPEG2000 [48, 51] , is also shown in Scheme 1.
Complex size and colloidal stability
CLeDNA complexes were formed by combining DNA and aqueous lipid preparations. All complexes were prepared at a fixed mol fraction of cationic lipid. To determine the colloidal stability of PEGylated and nonPEGylated CLeDNA complexes, we measured their mean hydrodynamic radius by dynamic light scattering (DLS). (Fig. 2A) . The steric shielding due to PEGylation reduces particleeparticle interaction, preventing aggregation even at low r. Thus, PEGylated complexes will remain colloidally stable in transfection medium for more than the incubation period (6 h) of cells with complexes, irrespective of PEG-lipid linker chemistry. Fig. 2B shows the sizes of PEGylated complexes (at r ¼ 2, where the size of nonPEGylated complexes is not stable over time) measured in buffers of increasing acidity at a total (buffer þ added salt) monovalent salt concentration of 150 mM, which is similar to that of Opti-MEM. The size of complexes incorporating the pH-stable PEG2K-lipid (red triangles) is essentially independent of solution pH and time over the investigated time period of 24 h, with a very small decrease in size with decreasing pH. In contrast, the size of HPEG2K-lipid containing complexes (blue inverse triangles) increases with decreasing pH in a time-dependent fashion. This indicates complex aggregation due to the acid-induced dePEGylation caused by cleavage of HPEG2K-lipids, demonstrating that the acid-sensitivity of the HPEG2K-lipid can be exploited when it is incorporated into CLeDNA complexes. Importantly, the pH threshold for dePEGylation, at pH 5, corresponds to the pH of maturing endosomes.
Transfection efficiency and cytotoxicity
We first assessed the effect of PEGylation on transfection efficiency using the model system of DOTAP/DOPCeDNA complexes at as yielding optimal TE for DOTAP/DOPCeDNA complexes [29] . Fig. 3 shows TE data for various DOTAP/DOPCeDNA complex formulations as function of r. In the absence of PEG-lipid (black solid squares), the maximum of TE occurs at r ¼ 3, and TE then slightly decreases with increasing r. Addition of 5 mol% PEG2K-lipid decreases TE by two orders of magnitudes at r ¼ 3, but the TE of these complexes increases with r to within an order of magnitude of the TE of nonPEGylated complexes at r ¼ 15 (Fig. 3A, red solid triangles). The addition of 10 mol% PEG2K-lipid (Fig. 3B , red open triangles) reduced TE to levels comparable to the TE of uncomplexed DNA (z10 6 RLU/mg protein). The TE of these complexes is almost independent of r, showing only a slight increase with r.
Replacing the pH-stable PEG2K-lipid with the acid-labile HPEG2K-lipid has a large effect on TE (Fig. 3, blue inverse triangles) . The TE of HPEG2K-containing complexes is higher for all data points and exhibits a maximum TE, at r ¼ 10, approaching the TE of nonPEGylated complexes at this r for both 5 and 10 mol% HPEG2K-lipid. Of note, 5 mol% PEG2000-lipid corresponds to full coverage of the bilayer with PEG chains in the mushroom conformation, while 10 mol% (the maximum amount that can be incorporated without phase separation) corresponds to PEG chains in the brush conformation, i.e., maximum sterical stabilization [53, 54] . Intriguingly, replacing PEG2K-lipid with the pH-sensitive HPEG2K-lipid only increases TE significantly at r > 3. The may be due to a reduction in complex stability cause by the incorporation of PEG-lipid, which is indicated by a lower total scattering intensity in DLS and fluorescence microscopy observations.
Complexes at higher CL to DNA charge ratios can exhibit lipidcaused vector toxicity [49, 55] . We thus measured cytotoxicity of the complexes used for TE measurements, employing a modified MTT assay [56] . Fig. 4 shows the results as percentage of viable cells against r. No notable toxicity was observed for any of the investigated complexes. In particular, the toxicity of optimized HPEGCLeDNA complexes (at r ¼ 10) approaches the background value and is identical (within error) to that of nonPEGylated complexes.
Live-cell imaging
To investigate the intracellular fate of PEGylated CLeDNA complexes directly, we performed epi-fluorescence microscopy on live cells using doubly labeled complexes. Thus, complexes were prepared with Cy5-labeled DNA (green in Fig. 5 ) and TRITC-DHPE as the lipid label (red in Fig. 5 ). Cells were treated with complexes as for transfection, and the location of the complexes was observed over time. HPEG2K-lipid. After 2 h of incubation, both types of complexes are seen attached to the plasma membrane. After 4 h, complexes containing the PEG2K-lipid appear as large, bright fluorescent spots while complexes containing the HPEG-lipid remain as small, point-like particles. As endosomes mature and fuse, more than one trapped complexes (such as complexes containing the PEG2K-lipid) may share the same endosomal compartment and become indistinguishable by fluorescent microscopy. The comparatively large fluorescent objects observed in (B) suggest that this is the case. In contrast, HPEG2K-CLeDNA complexes that escape from endosomes remain resolvable as individual particles due to the larger average spacing between them. Scale bars indicate 10 mm.
complexes exhibit maximum TE). At 2 h, both PEGylated CLeDNA complexes (yellow) are bound to the plasma membrane with a small number of complexes localized within the cytoplasm (Fig. 5A and C) , independent of the PEG-lipid used. After 4 h, fluorescent particles are seen inside of the cells in a punctuate pattern ( Fig. 5B and D) . A number of complexes are still observed bound to the plasma membrane after 4 h, suggesting a low rate constant for uptake once complexes are bound to the membrane. The imaging results were analyzed using an automated MatLab routine to quantitatively determine the intracellular spatial distribution of complexes. The resulting data is shown in Fig. 6 . Within the first 2 h, PEG2K-CLeDNA and HPEG2K-CLeDNA complexes show quantitatively similar uptake and cytoplasmic distribution, suggesting the difference in TE is due to differences in intracellular processing. However, at later time points, a larger number of HPEG2K-CLeDNA complexes were counted in the perinuclear region. An assessment of the actual images (cf. Fig. 6 ) suggests that this does not necessarily signify increased uptake. As endosomes mature and fuse (and travel to the perinuclear region, the location of the lysosomal compartment), several particles may share the same endosomal compartment and become indistinguishable by fluorescent microscopy as their separation is smaller than the resolution limit of the microscope. This effect should be more pronounced for particles that remain trapped in endosmes, i.e., PEG2K-CLeDNA complexes, which indeed show larger, brighter spots in the images. Conversely, HPEG2K-CLeDNA complexes primarily remain as small, point-like particles which remain spatially separated. This is indirect evidence of endosomal escape and could explain the divergence of the total number of internalized particles for the two types of complexes at later times.
Results for the multivalent lipid MVL5
Multivalent cationic lipids efficiently transfect over a broad range of composition and are superior to univalent cationic lipids as vectors for siRNA delivery and for DNA delivery to hard-to-transfect cells [43, 55] . This prompted us to investigate the effect of PEGylation on the TE of DNA complexes of the multivalent lipid MVL5 [46] . Thus, we prepared MVL5/DOPCeDNA complexes containing 0, 5 or 10 mol% of PEG2K-lipid or HPEG2K-lipid at F MVL5 ¼ 0.5 and r ¼ 10, which corresponds to the optimal TE for nonPEGylated complexes [29] . Fig. 7A shows the TE results, obtained as for DOTAP-containing complexes. Also shown is the TE of optimized DOTAP/DOPCeDNA complexes (cf. Fig. 3 ) and of the benchmark commercial reagent, Lipofectamine 2000. Without PEGylation, TE of MVL5/DOPCeDNA complexes is as high as that of Lipofectamine 2000 and higher than that of optimized DOTAP/DOPCeDNA complexes. Addition of 5 mol% PEG2K-lipid reduced TE, as observed for PEG2K-lipid/ DOTAP/DOPCeDNA complexes (cf. Fig. 3) . However, the MVL5-based complexes maintain a TE that is one order of magnitude higher than that of the DOTAP-containing complexes. Increasing the PEG2K-lipid content from 5 mol% to 10 mol% decreased TE by another order of magnitude to around 10 7 RLU/mg protein.
Replacing PEG2K-lipid with the acid-labile HPEG2K-lipid at 5 mol% HPEG2K-lipid recovered TE to essentially the level of nonPEGylated complexes. At 10 mol% PEG-lipid, however, replacing the PEG2K-lipid with the HPEG2K-lipid only recovered a small part of the lost TE, now to a level comparable to that of similar DOTAPcontaining complexes. This is further indication that addition of 10 mol% (H)PEG2K-lipid strongly reduces cell attachment and/or cell entry of complexes, in addition to inhibiting endosomal escape. The steric shielding in the brush regime effectively minimizes the complex-cell membrane interaction, and cell entry/attachment becomes a main barrier that limits the recovery of TE. We also assessed the cytotoxicity of PEGylated MVL5/ DOPCeDNA complexes at F MVL5 ¼ 0.5. Fig. 7B shows the percentage of viable cells as a function of r. As in the case of DOTAPcontaining complexes, no appreciable cytotoxicity is observed.
Conclusions
Using a custom-synthesized acid-labile PEG-lipid (HPEG2K-lipid) which is cleaved at the pH of maturing endosomes, we have investigated the contributions of two main barriers to transfection with PEGylated CLeDNA complexes in vitro: cellular uptake and endosomal escape. At 5 mol% PEG-lipid, steric stabilization of PEGylated CLeDNA complexes is efficient, and their TE is reduced by orders of magnitude over nonPEGylated complexes. Residual electrostatic attractions maintain cellular uptake of complexes that permits recovery of most of the TE (especially for complexes formed with multivalent MVL5) to near the level of nonPEGylated complexes upon replacing the stable PEG2K-lipid with the HPEG2K-lipid. This suggests that inhibition of endosomal escape is the main barrier for complexes containing 5 mol% PEG-lipid. At 10 mol% PEG-lipid, TE drops massively and is nearly independent of r, the lipid/DNA charge ratio. Here, the only moderate improvement observed on replacing PEG2K-lipid with HPEG2K-lipid suggests that poor cellular uptake has become a major barrier. All findings are consistent with our hypothesis that the low pH environment in late endosomes results in the removal of the PEGcoating of CLeDNA complexes prepared with the acid-labile HPEG2K-lipid, effectively switching on electrostatic forces required for optimal endosomal escape. Future work will combine selective attachment to cells via peptide or other ligands on the distal end of PEG-lipids with acid-labile PEG-lipids in the hope of achieving a synergistic effect.
